Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2021

Revenue From Contract With Customer [Abstract]

Product and Product-Related Service Revenue from Sale of Instruments and Consumables

Product and Product-related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three months ended March 31, 2021 and 2020 as follows:

	Three Months Ended March 31,
	2021		2020
Product revenue:
Instruments	$	224,013	$	234,625
Consumables		604,382		545,939
Total product revenue		828,395		780,564
Product-related services revenue:
Custom RUO assay design		48,350		629,182
RUO sample processing		558,401		578,391
Total product-related services revenue		606,751		1,207,573
Total product and product-related services revenue	$	1,435,146	$	1,988,137

Schedule of Collaborative Development Services

Collaborative Development Services Revenue

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. For the three months ended March 31, 2020, collaborative development services revenue was generated through statements of work entered into a Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”) discussed below.  

	Three Months Ended March 31,
	2021		2020
Collaborative development services	$	—	$	237,337

Schedule of Changes in Contract Liability

Changes in the Company’s contract liability were as follows as of the dates indicated:

	Product Revenue			Custom RUO Assay Design		Sample Processing			Total Contract Liability
Balance at January 1, 2021	$	103,580		$	-	$	93,884		$	197,464
Deferral of revenue		80,525			—		301,379			381,904
Recognition of deferred revenue		(57,795	)		—		(21,754	)		(79,549	)
Balance at March 31, 2021	$	126,310		$	—	$	373,509		$	499,819

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2020	$	95,148		$	66,216		$	438,090		$	599,454
Deferral of revenue		229,927			300,000			62,329			592,256
Recognition of deferred revenue		(214,712	)		(366,216	)		(30,119	)		(611,047	)
Balance at March 31, 2020	$	110,363		$	—		$	470,300		$	580,663